-
1
-
-
0022459307
-
Effect of differences in glucose tolerance on insulin's ability to regulate carbohydrate and free fatty acid metabolism in obese individuals
-
Golay A, Chen YDI, Reaven GM: Effect of differences in glucose tolerance on insulin's ability to regulate carbohydrate and free fatty acid metabolism in obese individuals. J Clin Endocrinol Metab 62:1081-1088, 1986
-
(1986)
J Clin Endocrinol Metab
, vol.62
, pp. 1081-1088
-
-
Golay, A.1
Chen, Y.D.I.2
Reaven, G.M.3
-
2
-
-
0013772833
-
Regulation of glucose uptake by muscle. IX. Effects of fatty acids and ketone bodies, and of alloxan diabetes and starvation, on pyruvate metabolism and on lactate/pyruvate and 1-glycerol 3-phosphate/dihydroxyacetone phosphate concentration ratios in rat heart and rat diaphragm muscles
-
Garland PB, Newsholme EA, Randle PJ: Regulation of glucose uptake by muscle. IX. Effects of fatty acids and ketone bodies, and of alloxan diabetes and starvation, on pyruvate metabolism and on lactate/pyruvate and 1-glycerol 3-phosphate/dihydroxyacetone phosphate concentration ratios in rat heart and rat diaphragm muscles. Biochem J 93:665-678, 1964
-
(1964)
Biochem J
, vol.93
, pp. 665-678
-
-
Garland, P.B.1
Newsholme, E.A.2
Randle, P.J.3
-
3
-
-
0026691368
-
Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo
-
Nuutila P, Koivisto VA, Knuuti J, et al: Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 89:1767-1774, 1992
-
(1992)
J Clin Invest
, vol.89
, pp. 1767-1774
-
-
Nuutila, P.1
Koivisto, V.A.2
Knuuti, J.3
-
4
-
-
0025178653
-
Operation of Randle's cycle in patients with NIDDM
-
Bevilacqua S, Buzzigoli G, Bonadonna R, et al: Operation of Randle's cycle in patients with NIDDM. Diabetes 39:383-389, 1990
-
(1990)
Diabetes
, vol.39
, pp. 383-389
-
-
Bevilacqua, S.1
Buzzigoli, G.2
Bonadonna, R.3
-
5
-
-
0021032715
-
Effect of fatty acids on glucose production and utilization in man
-
Ferrannini E, Barrett EJ, Bevilacqua S, et al: Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72:1737-1747, 1983
-
(1983)
J Clin Invest
, vol.72
, pp. 1737-1747
-
-
Ferrannini, E.1
Barrett, E.J.2
Bevilacqua, S.3
-
6
-
-
0025775034
-
Effects of lipid on basal carbohydrate metabolism in normal men
-
Boden G, Jadali F: Effects of lipid on basal carbohydrate metabolism in normal men. Diabetes 40:686-692, 1991
-
(1991)
Diabetes
, vol.40
, pp. 686-692
-
-
Boden, G.1
Jadali, F.2
-
7
-
-
0027475061
-
Contribution of muscle and liver to glucose-fatty acid cycle in humans
-
Saloranta C, Koivisto V, Widen E, et al: Contribution of muscle and liver to glucose-fatty acid cycle in humans. Am J Physiol 264:E599-E605, 1993
-
(1993)
Am J Physiol
, vol.264
-
-
Saloranta, C.1
Koivisto, V.2
Widen, E.3
-
8
-
-
0023237834
-
Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects
-
Bevilacqua S, Bonadonna R, Buzzigoli G, et al: Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism 36:502-506, 1987
-
(1987)
Metabolism
, vol.36
, pp. 502-506
-
-
Bevilacqua, S.1
Bonadonna, R.2
Buzzigoli, G.3
-
9
-
-
0025949378
-
Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin dependent diabetes mellitus
-
Vaag A, Skott P, Damsbo P, et al: Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin dependent diabetes mellitus. J Clin Invest 88:1282-1290, 1991
-
(1991)
J Clin Invest
, vol.88
, pp. 1282-1290
-
-
Vaag, A.1
Skott, P.2
Damsbo, P.3
-
10
-
-
0026644792
-
Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects
-
Fulcher GR, Walker M, Catalano C, et al: Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects. Diabetes 41:1400-1408, 1992
-
(1992)
Diabetes
, vol.41
, pp. 1400-1408
-
-
Fulcher, G.R.1
Walker, M.2
Catalano, C.3
-
11
-
-
0027515569
-
Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycaemia or total hepatic glucose production in NIDDM
-
Puhakainen I, Yki-Jarvinen H: Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycaemia or total hepatic glucose production in NIDDM. Diabetes 42:1694-1699, 1993
-
(1993)
Diabetes
, vol.42
, pp. 1694-1699
-
-
Puhakainen, I.1
Yki-Jarvinen, H.2
-
12
-
-
0026589396
-
Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: Effects of acipimox
-
Fulcher GR, Walker M, Catalano C, et al: Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: Effects of acipimox. Clin Sci 82:565-571, 1992
-
(1992)
Clin Sci
, vol.82
, pp. 565-571
-
-
Fulcher, G.R.1
Walker, M.2
Catalano, C.3
-
13
-
-
0028998846
-
The effect of 24-hour suppression of plasma nonesterified fatty acid levels on glucose and lipid metabolism in NIDDM
-
Davoren PM, Alberti KGMM: The effect of 24-hour suppression of plasma nonesterified fatty acid levels on glucose and lipid metabolism in NIDDM. Diabet Nutr Metab 8:17-23, 1995
-
(1995)
Diabet Nutr Metab
, vol.8
, pp. 17-23
-
-
Davoren, P.M.1
Alberti, K.G.M.M.2
-
14
-
-
0028203880
-
Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in non-insulin dependent diabetes mellitus patients during a 3-day intensified treatment period
-
Worm D, Henriksen JE, Vaag A, et al: Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in non-insulin dependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocrinol Metab 78:717-721, 1994
-
(1994)
J Clin Endocrinol Metab
, vol.78
, pp. 717-721
-
-
Worm, D.1
Henriksen, J.E.2
Vaag, A.3
-
15
-
-
0027493805
-
Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM
-
Saloranta C, Taskinen M, Widen E, et al: Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM. Diabetes 42:1559-1566, 1993
-
(1993)
Diabetes
, vol.42
, pp. 1559-1566
-
-
Saloranta, C.1
Taskinen, M.2
Widen, E.3
-
16
-
-
0000484708
-
The effect of nicotinic acid in diabetes mellitus
-
Molnar GD, Berge KG, Rosevear JW, et al: The effect of nicotinic acid in diabetes mellitus. Metabolism 13:181-189, 1964
-
(1964)
Metabolism
, vol.13
, pp. 181-189
-
-
Molnar, G.D.1
Berge, K.G.2
Rosevear, J.W.3
-
17
-
-
0025148561
-
Nicotinic acid therapy for treatment of dyslipidaemia in non-insulin dependent diabetes mellitus
-
Garg A, Grundy SM: Nicotinic acid therapy for treatment of dyslipidaemia in non-insulin dependent diabetes mellitus. JAMA 264:723-726, 1990
-
(1990)
JAMA
, vol.264
, pp. 723-726
-
-
Garg, A.1
Grundy, S.M.2
-
18
-
-
0019142367
-
Inhibition of lipolysis by nicotinic acid and acipimox
-
Fucella L, Goldaniga G, Lovisolo P, et al: Inhibition of lipolysis by nicotinic acid and acipimox. Clin Pharmacol Ther 28:790-795, 1980
-
(1980)
Clin Pharmacol Ther
, vol.28
, pp. 790-795
-
-
Fucella, L.1
Goldaniga, G.2
Lovisolo, P.3
-
19
-
-
0026489172
-
A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus
-
Fulcher GR, Catalano C, Walker M, et al: A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus. Diabet Med 9:908-914, 1992
-
(1992)
Diabet Med
, vol.9
, pp. 908-914
-
-
Fulcher, G.R.1
Catalano, C.2
Walker, M.3
-
20
-
-
0026473017
-
Effects of prolonged acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus
-
Copenh
-
Vaag AA, Beck-Nielsen H: Effects of prolonged acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus. Acta Endocrinol (Copenh) 127:344-350, 1992
-
(1992)
Acta Endocrinol
, vol.127
, pp. 344-350
-
-
Vaag, A.A.1
Beck-Nielsen, H.2
-
21
-
-
0026694047
-
The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia
-
Dean JD, McCarthy S, Betteridge DJ, et al: The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia. Diabet Med 9:611-615, 1992
-
(1992)
Diabet Med
, vol.9
, pp. 611-615
-
-
Dean, J.D.1
McCarthy, S.2
Betteridge, D.J.3
-
22
-
-
0027290746
-
Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinaemia by acipimox treatment
-
Koev D, Cvrkalova A, Rybka J, et al: Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinaemia by acipimox treatment. Diabetes Care 16:1285-1290, 1993
-
(1993)
Diabetes Care
, vol.16
, pp. 1285-1290
-
-
Koev, D.1
Cvrkalova, A.2
Rybka, J.3
-
23
-
-
0027328873
-
The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover
-
Seed M, O'Connor B, Perombelon N, et al: The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis 101:61-68, 1993
-
(1993)
Atherosclerosis
, vol.101
, pp. 61-68
-
-
Seed, M.1
O'Connor, B.2
Perombelon, N.3
-
24
-
-
0024466520
-
Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid
-
Carlson LA, Hamsten A, Asplund A: Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Int Med Res 226:271-276, 1989
-
(1989)
J Int Med Res
, vol.226
, pp. 271-276
-
-
Carlson, L.A.1
Hamsten, A.2
Asplund, A.3
-
25
-
-
0017670714
-
Glucose, insulin and somatostatin infusion for the determination of insulin sensitivity
-
Harano Y, Ohgaku S, Hidaka H, et al: Glucose, insulin and somatostatin infusion for the determination of insulin sensitivity. J Clin Endocrinol Metab 45:1124-1127, 1977
-
(1977)
J Clin Endocrinol Metab
, vol.45
, pp. 1124-1127
-
-
Harano, Y.1
Ohgaku, S.2
Hidaka, H.3
-
26
-
-
0021800286
-
A comparison of 3 methods for assessing insulin sensitivity in subjects with normal and abnormal glucose tolerance
-
Heine RJ, Home PD, Poncher M, et al: A comparison of 3 methods for assessing insulin sensitivity in subjects with normal and abnormal glucose tolerance. Diabetes Res 2:113-120, 1985
-
(1985)
Diabetes Res
, vol.2
, pp. 113-120
-
-
Heine, R.J.1
Home, P.D.2
Poncher, M.3
-
27
-
-
0021684350
-
Automated enzymatic determination of plasma free fatty acids by centrifugal analysis
-
Knox DP, Jones DG: Automated enzymatic determination of plasma free fatty acids by centrifugal analysis. J Automated Chem 6:152-154, 1984
-
(1984)
J Automated Chem
, vol.6
, pp. 152-154
-
-
Knox, D.P.1
Jones, D.G.2
-
28
-
-
0025633126
-
Optimized methods to measure acetoacetate, 3-hydroxybutyrate, glycerol, alanine, pyruvate, lactate and glucose in human blood using a centrifugal analyser with a fluorimetric attachment
-
Stappenbeck R, Hodson AW, Skillen AW, et al: Optimized methods to measure acetoacetate, 3-hydroxybutyrate, glycerol, alanine, pyruvate, lactate and glucose in human blood using a centrifugal analyser with a fluorimetric attachment. J Automatic Chem 12:213-220, 1990
-
(1990)
J Automatic Chem
, vol.12
, pp. 213-220
-
-
Stappenbeck, R.1
Hodson, A.W.2
Skillen, A.W.3
-
29
-
-
0026527767
-
Summarising laboratory data with difference ranges in multicenter clinical trials
-
Chuang-Stein C: Summarising laboratory data with difference ranges in multicenter clinical trials. Drug Inform J 26:77-84, 1992
-
(1992)
Drug Inform J
, vol.26
, pp. 77-84
-
-
Chuang-Stein, C.1
-
30
-
-
0023840497
-
Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridaemia
-
Taskinen M, Nikkila EA: Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridaemia. Atherosclerosis 69:249-255, 1988
-
(1988)
Atherosclerosis
, vol.69
, pp. 249-255
-
-
Taskinen, M.1
Nikkila, E.A.2
-
31
-
-
0022898291
-
Acipimox in the treatment of patients with hyperlipidaemia: A double blind trial
-
Ball MJ, Vella M, Reckless JPD, et al: Acipimox in the treatment of patients with hyperlipidaemia: A double blind trial. Eur J Clin Pharmacol 31:201-204, 1986
-
(1986)
Eur J Clin Pharmacol
, vol.31
, pp. 201-204
-
-
Ball, M.J.1
Vella, M.2
Reckless, J.P.D.3
-
32
-
-
0021997064
-
Effects of acipimox, a nicotinic acid derivative, on lipolysis in human adipose tissue and on cholesterol synthesis in human jejunal mucosa
-
Stirling C, McAleer M, Reckless JPD, et al: Effects of acipimox, a nicotinic acid derivative, on lipolysis in human adipose tissue and on cholesterol synthesis in human jejunal mucosa. Clin Sci 68:83-88, 1985
-
(1985)
Clin Sci
, vol.68
, pp. 83-88
-
-
Stirling, C.1
McAleer, M.2
Reckless, J.P.D.3
-
33
-
-
0030603999
-
Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia
-
Yang CY, Gu ZW, Xie YH, et al: Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia. Atherosclerosis 126:105-116, 1996
-
(1996)
Atherosclerosis
, vol.126
, pp. 105-116
-
-
Yang, C.Y.1
Gu, Z.W.2
Xie, Y.H.3
-
34
-
-
0029022637
-
Effect of simvastatin on Lp(a) concentrations
-
Haffner S, Orchard T, Stein E, et al: Effect of simvastatin on Lp(a) concentrations. Clin Cardiol 18:261-267, 1995
-
(1995)
Clin Cardiol
, vol.18
, pp. 261-267
-
-
Haffner, S.1
Orchard, T.2
Stein, E.3
-
35
-
-
0026660451
-
Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin
-
Slunga L, Johnson O, Dahlen GH: Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin. Eur J Clin Pharmacol 43:369-373, 1992
-
(1992)
Eur J Clin Pharmacol
, vol.43
, pp. 369-373
-
-
Slunga, L.1
Johnson, O.2
Dahlen, G.H.3
-
36
-
-
0024392514
-
Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus
-
Groop LC, Bonadonna RC, Delprato S, et al: Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus. J Clin Invest 84:205-213, 1989
-
(1989)
J Clin Invest
, vol.84
, pp. 205-213
-
-
Groop, L.C.1
Bonadonna, R.C.2
Delprato, S.3
-
37
-
-
0028357199
-
Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients
-
Hoffman J, Spengler M: Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. Diabetes Care 17:561-566, 1994
-
(1994)
Diabetes Care
, vol.17
, pp. 561-566
-
-
Hoffman, J.1
Spengler, M.2
-
38
-
-
0029064970
-
Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus
-
Coniff RF, Shapiro JA, Seaton TB, et al: Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 98:443-451, 1995
-
(1995)
Am J Med
, vol.98
, pp. 443-451
-
-
Coniff, R.F.1
Shapiro, J.A.2
Seaton, T.B.3
-
39
-
-
0029099086
-
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
-
DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
-
(1995)
N Engl J Med
, vol.333
, pp. 541-549
-
-
DeFronzo, R.A.1
Goodman, A.M.2
-
40
-
-
0027326414
-
Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea treated patients with NIDDM
-
Wolffenbuttel BH, Nijst L, Sels JP, et al: Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea treated patients with NIDDM. Eur J Clin Pharmacol 45:113-116, 1993
-
(1993)
Eur J Clin Pharmacol
, vol.45
, pp. 113-116
-
-
Wolffenbuttel, B.H.1
Nijst, L.2
Sels, J.P.3
-
41
-
-
13144288375
-
Clinical profile of glimeperide
-
Draeger E: Clinical profile of glimeperide. Diabetes Res Clin Pract 28:8139-8146, 1995 (suppl)
-
(1995)
Diabetes Res Clin Pract
, vol.28
, Issue.SUPPL.
, pp. 8139-8146
-
-
Draeger, E.1
-
42
-
-
0021691098
-
Relationships between insulin secretion, insulin action and fasting plasma glucose concentration in non-diabetic and non-insulin dependent diabetic subjects
-
Bogardus C, Lillioja S, Howard BV, et al: Relationships between insulin secretion, insulin action and fasting plasma glucose concentration in non-diabetic and non-insulin dependent diabetic subjects. J Clin Invest 74:1238-1246, 1984
-
(1984)
J Clin Invest
, vol.74
, pp. 1238-1246
-
-
Bogardus, C.1
Lillioja, S.2
Howard, B.V.3
-
43
-
-
0023189066
-
Relationships between plasma free fatty acid concentration, endogenous glucose production, and fasting hyperglycaemia in normal and non-insulin-dependent diabetic individuals
-
Golay A, Swislocki ALM, Chen YI, et al: Relationships between plasma free fatty acid concentration, endogenous glucose production, and fasting hyperglycaemia in normal and non-insulin-dependent diabetic individuals. Metabolism 36:692-696, 1987
-
(1987)
Metabolism
, vol.36
, pp. 692-696
-
-
Golay, A.1
Swislocki, A.L.M.2
Chen, Y.I.3
-
44
-
-
0027509296
-
Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate
-
Fulcher GR, Walker M, Farrer M, et al: Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate. Metabolism 42:308-314, 1993
-
(1993)
Metabolism
, vol.42
, pp. 308-314
-
-
Fulcher, G.R.1
Walker, M.2
Farrer, M.3
-
45
-
-
0029042116
-
The effect of acipimox on glucose disposal in non-insulin dependent diabetes is dependent on the lowering of nonesterified fatty acid levels
-
Davoren PM, Motala A, Alberti KGMM: The effect of acipimox on glucose disposal in non-insulin dependent diabetes is dependent on the lowering of nonesterified fatty acid levels. Diabet Nutr Metab 8:99-104, 1995
-
(1995)
Diabet Nutr Metab
, vol.8
, pp. 99-104
-
-
Davoren, P.M.1
Motala, A.2
Alberti, K.G.M.M.3
-
46
-
-
0019370336
-
Pharmacological profile of a new anti-lipolytic agent: 5-Methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox). I. Mechanism of action
-
Lovisolo PP, Briatico-Vangosa G, Orsini G, et al: Pharmacological profile of a new anti-lipolytic agent: 5-Methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox). I. Mechanism of action. Pharmacol Res Commun 13:151-161, 1981
-
(1981)
Pharmacol Res Commun
, vol.13
, pp. 151-161
-
-
Lovisolo, P.P.1
Briatico-Vangosa, G.2
Orsini, G.3
-
47
-
-
0030031015
-
Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes
-
Christie AW, McCormick DKT, Emmison N, et al: Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes. Diabetologia 39:45-53, 1996
-
(1996)
Diabetologia
, vol.39
, pp. 45-53
-
-
Christie, A.W.1
McCormick, D.K.T.2
Emmison, N.3
|